[EN] PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS<br/>[FR] COMPOSES
申请人:ASTRAZENECA AB
公开号:WO2006024823A1
公开(公告)日:2006-03-09
A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.
PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
申请人:AstraZeneca AB
公开号:EP1809624A1
公开(公告)日:2007-07-25
EP2301933A1
申请人:——
公开号:EP2301933A1
公开(公告)日:2011-03-30
Haptens, hapten conjugates, compositions thereof and method for their preparation and use
申请人:Kosmeder Jerome W.
公开号:US20080268462A1
公开(公告)日:2008-10-30
A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.